Ferring Pharmaceuticals Presents Phase III Data for a Controlled Release Misoprostol Vaginal Delivery System for Labour Induction at the First European Congress on Intrapartum Care
5/28/2013 11:30:14 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
AMSTERDAM--(BUSINESS WIRE)--Data from the EXPEDITE study presented today at the First European Congress on Intrapartum Care (ECIC) demonstrated that use of a controlled release misoprostol vaginal insert significantly reduced time to vaginal delivery compared to a dinoprostone vaginal insert.1
Help employers find you! Check out all the jobs and post your resume.
comments powered by